STOCK TITAN

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
conferences

Prime Medicine, a biotechnology company specializing in one-time curative genetic therapies, has announced that its President and CEO, Keith Gottesdiener, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA.

A live audio webcast of the presentation will be accessible under the “Events & Presentations” section on the company’s website, www.primemedicine.com. Additionally, a replay of the webcast will be available on the website for 30 days after the presentation.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+0.31% News Effect

On the day this news was published, PRME gained 0.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA.

A live audio webcast of the presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 30 days following the presentation.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology and oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Investor Contact
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

Media Contact
Dan Budwick, 1AB
dan@1ABmedia.com


FAQ

When will Prime Medicine present at the J.P. Morgan Healthcare Conference?

Prime Medicine will present on Tuesday, January 14, 2025, at 3:00 p.m. PT (6:00 p.m. ET).

Who is presenting for Prime Medicine at the J.P. Morgan Healthcare Conference?

Keith Gottesdiener, M.D., the President and CEO of Prime Medicine, will present at the conference.

Where can I watch Prime Medicine's presentation at the J.P. Morgan Healthcare Conference?

A live audio webcast of the presentation will be available on Prime Medicine's website under the 'Events & Presentations' section.

How long will the replay of Prime Medicine’s presentation be available?

The replay will be available on Prime Medicine's website for 30 days following the presentation.

What is the stock symbol for Prime Medicine?

The stock symbol for Prime Medicine is PRME.

What type of therapies does Prime Medicine specialize in?

Prime Medicine specializes in one-time curative genetic therapies.

Where is Prime Medicine presenting its corporate overview?

Prime Medicine is presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

What time is Prime Medicine's presentation in Eastern Time?

Prime Medicine's presentation will be at 6:00 p.m. ET.
Prime Medicine

NASDAQ:PRME

PRME Rankings

PRME Latest News

PRME Latest SEC Filings

PRME Stock Data

637.20M
148.58M
18.19%
44.28%
10.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE